The Wilms tumor gene (WT1) biomarker is used in the prognosis and follow-up of normal karyotype acute myeloid leukemia (AML) patients, who account for nearly half of AML adult patients. Quantification of WT1 expression level helps predict disease aggressiveness and determine patient response to treatment, said Ipsogen.
In a recent European study, WT1 proved to be a reliable indicator that can be used for minimal residual disease monitoring distinguishing patients at differing risk of relapse, the company said.
The WT1 assay has been developed in the context of a collaborative project coordinated by the European Leukemia Network consortium, systematically evaluating nine different available assays to identify the best performing one, the company added.
Vincent Fert, founder and CEO of Ipsogen, said: “The CE marking of our ProfileQuant WT1 will further increase the adoption of this marker by European laboratories. This test provides oncologists and hematologists with a more precise picture of pathological processes and disease evolution, and will help them to tailor their treatment strategy for each individual AML patient, a critical need in a disease where only 60% of normal karyotype AML patients survive on the long term.”